

**Dual Viral Vector Mediated Persistent CRISPR-Cas9 Gene Disruption  
in Primary Human Endothelial Cells**

**Supplementary Information**

Haixia Gong<sup>1,2†</sup>, Menglin Liu<sup>1,2†</sup>, Jeff Klomp<sup>1,2</sup>, Bradley J Merrill<sup>3,4</sup>,

Jalees Rehman<sup>1,2,5\*</sup>, and Asrar B. Malik<sup>1,2\*</sup>

<sup>1</sup>Department of Pharmacology, <sup>2</sup>The Center for Lung and Vascular Biology, <sup>3</sup>Department of Biochemistry and Molecular Genetics, <sup>4</sup>Genome Editing Core, and <sup>5</sup>Division of Cardiology, Department of Medicine, University of Illinois College of Medicine, Chicago, IL 60612, USA.

† contributed equally to the work

For correspondence:

Asrar B. Malik PhD or Jalees Rehman MD,

E-mail: [abmalik@uic.edu](mailto:abmalik@uic.edu) or [jalees@uic.edu](mailto:jalees@uic.edu)

### Supplementary Figure Legends

**Figure S1.** Full length gels for Figure 1B. Immunoblotting of Tie2 protein in vector control, Tie2 knockout HLMVECs induced by CRISPR-Cas9 (sgRNA Tie2-1, sgRNA Tie2-2), and mouse Tie2 overexpression in Tie2<sup>-/-</sup> HLMVECs (HuTie2KO1 + mTie2, HuTie2KO2 + mTie2,). The pictures of target proteins (chemiluminescence) and protein ladder standards (fluorescence) can only be taken separately by ImageQuant LAS 4000 software. GAPDH was used as the loading control.

Figure S1

